HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target
Benzinga Newsdesk 8 months ago
NewsPrice TargetReiterationAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Brandon Folkes reiterates Pelthos Therapeutics (AMEX:PTHS) with a Buy and maintains $60 price target.
HC Wainwright & Co. analyst Brandon Folkes reiterates Pelthos Therapeutics (AMEX:PTHS) with a Buy and maintains $60 price target.
